Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Merck (MRK) may be a storied pharmaceutical giant with a 134-year history, but it still has a lot of room to run. Merck is ...

The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with ...

- Non-GAAP EPS of $2.13 topped estimates by $0.11 in Q2 2025; GAAP revenue of $15.8 billion missed by $93 million in Q2 2025. - KEYTRUDA oncology drug sales climbed 9% in Q2 2025, while GARDASIL ...

We expect Moderna MRNA to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory syncytial virus (RSV) preventive developed by French drugmaker Sanofi and ...

The federal government is recommending flu vaccines remove the preservative thimerosal after Health and Human Services ...

McDermott Will & Emergy has hired Merck’s head of legal for M&A as a Frankfurt partner, reflecting the growing trend of senior in-house lawyers moving back into private practice.

Merck & Co., Inc. (NYSE:MRK) further mentioned that the typical RSV season generally spans autumn to spring of the next year. A close-up of a person’s hand holding a bottle of pharmaceuticals.